{"id":"https://openalex.org/W2588338482","doi":"https://doi.org/10.1182/blood.v108.11.3396.3396","title":"Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma.","display_name":"Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma.","publication_year":2006,"publication_date":"2006-11-16","ids":{"openalex":"https://openalex.org/W2588338482","doi":"https://doi.org/10.1182/blood.v108.11.3396.3396","mag":"2588338482"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v108.11.3396.3396","doi":"https://doi.org/10.1182/blood.v108.11.3396.3396","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v108.11.3396.3396","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006765393","display_name":"Dharminder Chauhan","orcid":"https://orcid.org/0000-0002-5548-6138","observed_orcids":["https://orcid.org/0000-0002-5548-6138"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dharminder Chauhan","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102256659","display_name":"Ajita Singh","orcid":"https://orcid.org/0000-0002-6070-4232","observed_orcids":["https://orcid.org/0000-0002-6070-4232"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ajita Singh","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018185328","display_name":"Mugdha Velankar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Mugdha Velankar","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091207345","display_name":"Teru Hideshima","orcid":"https://orcid.org/0000-0003-2939-6224","observed_orcids":["https://orcid.org/0000-0003-2939-6224"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Teru Hideshima","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088622927","display_name":"Huib Ovaa","orcid":"https://orcid.org/0000-0002-0068-054X","observed_orcids":["https://orcid.org/0000-0002-0068-054X"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Huib Ovaa","raw_affiliation_strings":["Div. of Cellular Biochemistry, Netherlands Cancer Institute, Amsterdam, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Div. of Cellular Biochemistry, Netherlands Cancer Institute, Amsterdam, Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062435332","display_name":"Celia R. Berkers","orcid":"https://orcid.org/0000-0003-0746-8565","observed_orcids":["https://orcid.org/0000-0003-0746-8565"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Celia Berkers","raw_affiliation_strings":["Div. of Cellular Biochemistry, Netherlands Cancer Institute, Amsterdam, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Div. of Cellular Biochemistry, Netherlands Cancer Institute, Amsterdam, Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084831561","display_name":"Giada Bianchi","orcid":"https://orcid.org/0000-0003-3673-0104","observed_orcids":["https://orcid.org/0000-0003-3673-0104"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Giada Bianchi","raw_affiliation_strings":["DiBiT, San Raffaele Scientific Institute & University, Milano, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DiBiT, San Raffaele Scientific Institute & University, Milano, Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073518488","display_name":"Roberto Sitia","orcid":"https://orcid.org/0000-0001-7086-4152","observed_orcids":["https://orcid.org/0000-0001-7086-4152"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Roberto Sitia","raw_affiliation_strings":["DiBiT, San Raffaele Scientific Institute & University, Milano, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DiBiT, San Raffaele Scientific Institute & University, Milano, Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045740077","display_name":"Nikhil C. Munshi","orcid":"https://orcid.org/0000-0002-7344-9795","observed_orcids":["https://orcid.org/0000-0002-7344-9795","https://orcid.org/0000-0002-8397-100X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nikhil C. Munshi","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Richardson","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000260833","display_name":"Michael A. Palladino","orcid":"https://orcid.org/0000-0002-4687-7612","observed_orcids":["https://orcid.org/0000-0002-4687-7612"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Michael A. Palladino","raw_affiliation_strings":["Nereus Pharmaceuticals, San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nereus Pharmaceuticals, San Diego, CA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth C. Anderson","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5000260833","https://openalex.org/A5018185328","https://openalex.org/A5062435332","https://openalex.org/A5073518488","https://openalex.org/A5084831561","https://openalex.org/A5088622927","https://openalex.org/A5102256659"],"corresponding_institution_ids":["https://openalex.org/I2898336195","https://openalex.org/I4210117453"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.61,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.73810737,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"108","issue":"11","first_page":"3396","last_page":"3396"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9448000192642212,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9448000192642212,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.0502999983727932,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/npi-0052","display_name":"NPI-0052","score":0.996999979019165},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9940000176429749},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.8980000019073486},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.9179999828338623},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.906000018119812},{"id":"https://openalex.org/keywords/mm-1s-cells","display_name":"MM.1S cells","score":0.8859999775886536},{"id":"https://openalex.org/keywords/nf-kappab-signaling","display_name":"NF-\u03baB signaling","score":0.8379999995231628},{"id":"https://openalex.org/keywords/endoplasmic-reticulum-stress","display_name":"endoplasmic reticulum stress","score":0.8090000152587891},{"id":"https://openalex.org/keywords/gadd153","display_name":"GADD153","score":0.9710000157356262},{"id":"https://openalex.org/keywords/caspase-4","display_name":"caspase-4","score":0.9580000042915344},{"id":"https://openalex.org/keywords/proteasome-inhibition","display_name":"proteasome inhibition","score":0.7390000224113464},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.4350000023841858}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.9742783904075623},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.7812119722366333},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.7748674750328064},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7644201517105103},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5524430274963379},{"id":"https://openalex.org/C53227056","wikidata":"https://www.wikidata.org/wiki/Q189152","display_name":"Viability assay","level":3,"score":0.5268629789352417},{"id":"https://openalex.org/C2777752497","wikidata":"https://www.wikidata.org/wiki/Q286779","display_name":"IC50","level":3,"score":0.48899638652801514},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.466198593378067},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4353676438331604},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.43306130170822144},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4098649024963379},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3803059756755829},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2515769600868225},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.16440647840499878},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0936204195022583},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v108.11.3396.3396","doi":"https://doi.org/10.1182/blood.v108.11.3396.3396","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v108.11.3396.3396","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1987583882","https://openalex.org/W4249088156","https://openalex.org/W2910942915","https://openalex.org/W2243792761","https://openalex.org/W7096145386","https://openalex.org/W2243925837","https://openalex.org/W1946046850","https://openalex.org/W2126885291","https://openalex.org/W2560359838","https://openalex.org/W1595109869"],"abstract_inverted_index":{"Abstract":[0],"Our":[1],"recent":[2],"study":[3],"showed":[4,187,373],"that":[5,113,188,295,307,374,440],"a":[6,124,138,151,238,255,292,392,413],"novel":[7],"proteasome":[8,31,275,293,301,332,454],"inhibitor":[9,294],"NPI-0052,":[10,213,427],"like":[11,214],"bortezomib,":[12,215,431],"triggers":[13],"apoptosis":[14,447],"in":[15,25,57,97,127,144,398,415,428],"multiple":[16],"myeloma":[17],"(MM)":[18],"cells":[19,156,193,205,247],"but":[20,459],"is":[21,120,380,448],"distinct":[22],"from":[23],"bortezomib":[24,84,131,232,251,264,289,314,340],"its":[26],"chemical":[27],"structure,":[28],"effects":[29],"on":[30,184],"activities,":[32],"and":[33,106,169,203,219,290,319,346,348,389,425,445,463],"mechanisms":[34],"of":[35,49,68,116,134,141,162,181,241,245,259,274,300,331,371,453],"action":[36],"(Chauhan":[37],"et":[38],"al.,":[39],"Cancer":[40],"Cell,":[41],"2005,":[42],"8:407\u2013419).":[43],"Here":[44],"we":[45],"examined":[46,271],"the":[47,64,182,189,272,356,366,465],"time-kinetics":[48],"early":[50],"events":[51],"triggered":[52,277],"by":[53,149,229,261,278,311,317,321,362,386],"these":[54,437],"two":[55],"agents":[56],"MM.1S":[58,155,246],"MM":[59],"cells.":[60,179],"We":[61,209,269],"first":[62],"determined":[63,211],"minimum":[65],"exposure":[66,117,135,235,378,422],"time":[67,379],"drug":[69],"required":[70],"to":[71,79,118,122,136,236,382,400,423,430,468,474],"trigger":[72,123,137],"an":[73,103],"irreversible":[74],"apoptosis.":[75,142],"Cells":[76,334],"were":[77,147,157,284,335,351],"exposed":[78],"NPI-0052":[80,119,222,249,262,279,287,312,338,388,401,405,469],"(IC50:7":[81],"nM)":[82,86],"or":[83,94,250,280,288,313,339],"(IC50:5":[85],"for":[87,102,108,165,252,328,341,353],"15":[88,114],"min,":[89,91,343,411],"30":[90,166,342,376,410],"1h,":[92,230,344],"3h":[93,421],"6h,":[95],"cultured":[96],"regular":[98],"medium":[99],"without":[100],"drugs":[101],"additional":[104],"24h;":[105],"analyzed":[107],"viability.":[109],"The":[110],"results":[111],"demonstrate":[112],"min":[115,167,377],"sufficient":[121,381],"50%":[125,224],"decrease":[126,383,414],"cell":[128],"viability,":[129],"whereas":[130,198,231,412],"requires":[132,233],"6h":[133,234],"similar":[139,239],"extent":[140,273],"These":[143],"vitro":[145],"data":[146],"confirmed":[148],"using":[150],"human":[152],"MM-xenograft":[153],"model:":[154],"treated":[158,336],"with":[159,176,191,201,248,266,302,324,337,355,365,450,460],"IC50":[160],"doses":[161],"each":[163],"agent":[164],"ex-vivo":[168],"injected":[170,200],"into":[171],"immunodeficient":[172],"BNX":[173],"mice":[174,190,199],"along":[175,265],"untreated":[177,202],"control":[178],"Examination":[180],"tumors":[183],"day":[185],"21":[186],"NPI-0052-treated":[192],"develop":[194],"no":[195],"significant":[196,207],"tumor,":[197],"bortezomib-treated":[204],"developed":[206],"tumor.":[208],"next":[210,270],"whether":[212],"affects":[216],"NF-\u03baB":[217,225],"signaling":[218],"ER-stress":[220],"responses.":[221],"inhibits":[223,406,432],"DNA":[226],"binding":[227],"activity":[228,385,408],"cause":[237],"degree":[240],"inhibition.":[242],"Moreover,":[243],"treatment":[244],"5h":[253],"shows":[254],"more":[256,394],"robust":[257,395],"induction":[258],"GADD153":[260],"than":[263,402,473],"caspase-4":[267],"activation.":[268],"inhibition":[276,396],"bortezomib.":[281,475],"Competition":[282],"experiments":[283],"performed":[285],"between":[286],"dansyl-Ahx3L3VS,":[291],"targets":[296],"all":[297],"active":[298],"subunits":[299],"comparable":[303],"affinity:":[304],"specifically,":[305],"sites":[306],"are":[308,315],"not":[309],"targeted":[310],"labeled":[316],"dansyl-Ahx3L3VS":[318,357],"visualized":[320],"subsequent":[322],"immunoblotting":[323],"anti-dansyl":[325,367],"Abs,":[326],"allowing":[327],"quantitative":[329],"assessment":[330],"activity.":[333,434],"3h,":[345],"6h;":[347],"protein":[349],"extracts":[350],"incubated":[352],"2h":[354],"probe":[358],"at":[359,409],"37\u00b0C,":[360],"followed":[361],"immunoblot":[363,372],"analysis":[364,370],"Abs.":[368],"Densitometric":[369],"1)":[375,441],"Chymotrypsin-like":[384],"both":[387,443],"bortezomib;":[390,403,424],"however,":[391],"much":[393,471],"occurs":[397,470],"response":[399,467],"2)":[404,464],"caspase-like":[407],"C-L":[416],"was":[417],"noted":[418],"only":[419],"after":[420],"3)":[426],"contrast":[429],"trypsin-like":[433],"Taken":[435],"together,":[436],"findings":[438],"suggest":[439],"although":[442],"NPI-0052-":[444],"bortezomib-triggered":[446],"associated":[449],"sequential":[451],"occurrence":[452],"inhibition>NF-\u03baB>":[455],"blockade>ER":[456],"stress":[457],"induction,":[458],"differential":[461],"kinetics,":[462],"cellular":[466],"earlier":[472]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-02-24T00:00:00"}